Abstract
11049 Background: Prosigna has been clinically validated in 2 large randomized studies to predict the risk of distant and late recurrence in HR+/HER2- patients treated with endocrine therapy.NAC ef...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have